By staff writers

January 12, 2017 -- The U.S. Food and Drug Administration (FDA) has cleared contrast developer Bracco Diagnostics' Lumason agent for use in ultrasound of the urinary tract in pediatric patients.

The procedure is indicated to evaluate suspected or known vesicoureteral reflux, a urinary tract abnormality in newborns, infants, and children. It offers an alternative to current procedures, which expose children to radiation, Bracco said.

Copyright © 2017

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking